ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis

NASDAQ:ACAD • US0042251084

22.8299 USD
+0.8 (+3.63%)
Last: Feb 17, 2026, 01:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

ACAD gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. ACAD has an excellent financial health rating, but there are some minor concerns on its profitability. ACAD is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make ACAD suitable for value investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year ACAD was profitable.
  • In the past year ACAD had a positive cash flow from operations.
  • In the past 5 years ACAD always reported negative net income.
  • In the past 5 years ACAD always reported negative operating cash flow.
ACAD Yearly Net Income VS EBIT VS OCF VS FCFACAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 19.63%, ACAD belongs to the top of the industry, outperforming 96.93% of the companies in the same industry.
  • ACAD has a Return On Equity of 28.47%. This is amongst the best in the industry. ACAD outperforms 97.12% of its industry peers.
  • ACAD has a better Return On Invested Capital (7.66%) than 93.47% of its industry peers.
Industry RankSector Rank
ROA 19.63%
ROE 28.47%
ROIC 7.66%
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ACAD Yearly ROA, ROE, ROICACAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • Looking at the Profit Margin, with a value of 24.94%, ACAD belongs to the top of the industry, outperforming 94.82% of the companies in the same industry.
  • ACAD has a better Operating Margin (9.02%) than 90.98% of its industry peers.
  • Looking at the Gross Margin, with a value of 91.92%, ACAD belongs to the top of the industry, outperforming 93.28% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ACAD has grown nicely.
Industry RankSector Rank
OM 9.02%
PM (TTM) 24.94%
GM 91.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
ACAD Yearly Profit, Operating, Gross MarginsACAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ACAD is destroying value.
  • ACAD has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ACAD has more shares outstanding
  • There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACAD Yearly Shares OutstandingACAD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ACAD Yearly Total Debt VS Total AssetsACAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • ACAD has an Altman-Z score of 4.88. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
  • ACAD has a better Altman-Z score (4.88) than 72.94% of its industry peers.
  • There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.88
ROIC/WACC0.88
WACC8.68%
ACAD Yearly LT Debt VS Equity VS FCFACAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.02 indicates that ACAD has no problem at all paying its short term obligations.
  • ACAD has a worse Current ratio (3.02) than 63.92% of its industry peers.
  • ACAD has a Quick Ratio of 2.94. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ACAD (2.94) is worse than 62.38% of its industry peers.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.94
ACAD Yearly Current Assets VS Current LiabilitesACAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • ACAD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.10%.
  • ACAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 121.75%.
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%

3.2 Future

  • Based on estimates for the next years, ACAD will show a very strong growth in Earnings Per Share. The EPS will grow by 38.44% on average per year.
  • Based on estimates for the next years, ACAD will show a quite strong growth in Revenue. The Revenue will grow by 10.58% on average per year.
EPS Next Y70.03%
EPS Next 2Y26.24%
EPS Next 3Y33.41%
EPS Next 5Y38.44%
Revenue Next Year11.07%
Revenue Next 2Y11.15%
Revenue Next 3Y10.89%
Revenue Next 5Y10.58%

3.3 Evolution

ACAD Yearly Revenue VS EstimatesACAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 500M 1B 1.5B 2B
ACAD Yearly EPS VS EstimatesACAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 34.07, the valuation of ACAD can be described as expensive.
  • 92.51% of the companies in the same industry are more expensive than ACAD, based on the Price/Earnings ratio.
  • ACAD is valuated rather expensively when we compare the Price/Earnings ratio to 27.19, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 29.84, the valuation of ACAD can be described as expensive.
  • Based on the Price/Forward Earnings ratio, ACAD is valued cheaply inside the industry as 91.94% of the companies are valued more expensively.
  • ACAD is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 34.07
Fwd PE 29.84
ACAD Price Earnings VS Forward Price EarningsACAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaper than 94.24% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, ACAD is valued cheaper than 95.97% of the companies in the same industry.
Industry RankSector Rank
P/FCF 17.74
EV/EBITDA 21.12
ACAD Per share dataACAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of ACAD may justify a higher PE ratio.
  • A more expensive valuation may be justified as ACAD's earnings are expected to grow with 33.41% in the coming years.
PEG (NY)0.49
PEG (5Y)N/A
EPS Next 2Y26.24%
EPS Next 3Y33.41%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ACAD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACADIA PHARMACEUTICALS INC

NASDAQ:ACAD (2/17/2026, 1:02:09 PM)

22.8299

+0.8 (+3.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)02-25
Inst Owners101.21%
Inst Owner Change-2.33%
Ins Owners0.26%
Ins Owner Change-3.07%
Market Cap3.86B
Revenue(TTM)1.05B
Net Income(TTM)261.17M
Analysts76.92
Price Target31.73 (38.98%)
Short Float %5.56%
Short Ratio6.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.34%
Min EPS beat(2)14.46%
Max EPS beat(2)178.22%
EPS beat(4)2
Avg EPS beat(4)20.1%
Min EPS beat(4)-109.07%
Max EPS beat(4)178.22%
EPS beat(8)5
Avg EPS beat(8)29%
EPS beat(12)7
Avg EPS beat(12)26.97%
EPS beat(16)10
Avg EPS beat(16)24.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.19%
Max Revenue beat(2)-0.93%
Revenue beat(4)1
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)6
Avg Revenue beat(16)-1.45%
PT rev (1m)5.91%
PT rev (3m)6.68%
EPS NQ rev (1m)-9.12%
EPS NQ rev (3m)1.73%
EPS NY rev (1m)-0.91%
EPS NY rev (3m)39.89%
Revenue NQ rev (1m)-0.35%
Revenue NQ rev (3m)0.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.91%
Valuation
Industry RankSector Rank
PE 34.07
Fwd PE 29.84
P/S 3.69
P/FCF 17.74
P/OCF 12.16
P/B 4.21
P/tB 4.79
EV/EBITDA 21.12
EPS(TTM)0.67
EY2.93%
EPS(NY)0.77
Fwd EY3.35%
FCF(TTM)1.29
FCFY5.64%
OCF(TTM)1.88
OCFY8.23%
SpS6.19
BVpS5.42
TBVpS4.76
PEG (NY)0.49
PEG (5Y)N/A
Graham Number9.04
Profitability
Industry RankSector Rank
ROA 19.63%
ROE 28.47%
ROCE 9.69%
ROIC 7.66%
ROICexc 58.65%
ROICexgc 479.54%
OM 9.02%
PM (TTM) 24.94%
GM 91.92%
FCFM 20.79%
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
F-Score4
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 711.57%
Cap/Sales 9.55%
Interest Coverage 250
Cash Conversion 292.92%
Profit Quality 83.36%
Current Ratio 3.02
Quick Ratio 2.94
Altman-Z 4.88
F-Score4
WACC8.68%
ROIC/WACC0.88
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)567.7%
Cap/Sales(5y)341.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y70.03%
EPS Next 2Y26.24%
EPS Next 3Y33.41%
EPS Next 5Y38.44%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
Revenue Next Year11.07%
Revenue Next 2Y11.15%
Revenue Next 3Y10.89%
Revenue Next 5Y10.58%
EBIT growth 1Y50.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.83%
EBIT Next 3Y26.42%
EBIT Next 5Y33.87%
FCF growth 1Y264.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y443.26%
OCF growth 3YN/A
OCF growth 5YN/A

ACADIA PHARMACEUTICALS INC / ACAD FAQ

What is the fundamental rating for ACAD stock?

ChartMill assigns a fundamental rating of 6 / 10 to ACAD.


What is the valuation status of ACADIA PHARMACEUTICALS INC (ACAD) stock?

ChartMill assigns a valuation rating of 7 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Undervalued.


Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?

ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of ACADIA PHARMACEUTICALS INC (ACAD) stock?

The Price/Earnings (PE) ratio for ACADIA PHARMACEUTICALS INC (ACAD) is 34.07 and the Price/Book (PB) ratio is 4.21.


Can you provide the financial health for ACAD stock?

The financial health rating of ACADIA PHARMACEUTICALS INC (ACAD) is 7 / 10.